J. Benjamin Hurlbut
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. Benjamin Hurlbut has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Krishanu Saha
Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, USA
3 shared publications Abha Saxena
World Health Organization, Geneva, Switzerland
2 shared publicationsAnthony Appiah
New York University, New York, NY, USA http://www.twitter.com/KAnthonyAppiah
2 shared publicationsAziza Ahmed
Northeastern University School of Law, Boston, MA, USA http://www.twitter.com/AzizaAhmed
2 shared publicationsBuhm Soon Park
Korea Advanced Institute of Science and Technology, Daejeon, South Korea
2 shared publicationsChristiane Woopen
Research Unit Ethics and CERES, University of Cologne http://www.twitter.com/CWoopen
2 shared publications
Latest Publications
- 9 August 2023
- Published by Springer Nature
- p. C1
Correction to: Limits of Debate: Governance of Human Embryo Research and the Making of the Fourteen-Day Rule
- 9 August 2023
- Published by Springer Nature
- p. C1
Correction to: Limits of Debate: Governance of Human Embryo Research and the Making of the Fourteen-Day Rule
- 15 June 2023
- Published by Springer Nature
- p. 145-161
Limits of Debate: Governance of Human Embryo Research and the Making of the Fourteen-Day Rule
- 15 June 2023
- Published by Springer Nature
- p. 145-161
Limits of Debate: Governance of Human Embryo Research and the Making of the Fourteen-Day Rule
- 6 February 2020
- Published by Springer Nature
- p. 249-268
Behold the Man: Figuring the Human in the Development of Biotechnology
- 6 February 2020
- Published by Springer Nature
- p. 249-268
Behold the Man: Figuring the Human in the Development of Biotechnology
- 1 January 2020
- Published by Project MUSE in Perspectives in Biology and Medicine
- Vol. 63 (1) , 177-194
Imperatives of Governance: Human Genome Editing and the Problem of Progress
The ability to make direct genetic changes to the DNA of future children poses profound challenges for governance. Over the last several years, efforts to establish frameworks of ethical deliberation and governance for human genome editing have focused largely on technical criteria for proceeding with research and rules and mechanisms for regulating it. Less attention has been given to the question of who decides, and on the basis of what authority. The power to decide is exercised not only in giving answers to ethical questions or suppling policy advice, but in designating what questions should (and should not) be asked in the first place. The ways problems are framed and terms of collective debate are set is a crucial element of governance. This essay examines how certain framings that have dominated in influential arenas of deliberation about human germline genome editing underwrite (false) imperatives of governance. These imperatives have shaped not only ethical deliberation and governance agendas, but the trajectory of science itself. The essay focuses in particular upon the case of He Jiankui, arguing that his project is not an aberration, but, rather, an expression of ideas about science, ethics, and progress that are widely shared within the scientific community.
- 1 January 2020
- Published by Project MUSE in Perspectives in Biology and Medicine
- Vol. 63 (1) , 177-194
Imperatives of Governance: Human Genome Editing and the Problem of Progress
The ability to make direct genetic changes to the DNA of future children poses profound challenges for governance. Over the last several years, efforts to establish frameworks of ethical deliberation and governance for human genome editing have focused largely on technical criteria for proceeding with research and rules and mechanisms for regulating it. Less attention has been given to the question of who decides, and on the basis of what authority. The power to decide is exercised not only in giving answers to ethical questions or suppling policy advice, but in designating what questions should (and should not) be asked in the first place. The ways problems are framed and terms of collective debate are set is a crucial element of governance. This essay examines how certain framings that have dominated in influential arenas of deliberation about human germline genome editing underwrite (false) imperatives of governance. These imperatives have shaped not only ethical deliberation and governance agendas, but the trajectory of science itself. The essay focuses in particular upon the case of He Jiankui, arguing that his project is not an aberration, but, rather, an expression of ideas about science, ethics, and progress that are widely shared within the scientific community.
- 1 August 2018
- Published by Elsevier in Trends in Biotechnology
- Vol. 36 (8) , 741-743
Building Capacity for a Global Genome Editing Observatory: Institutional Design
- 1 August 2018
- Published by Elsevier in Trends in Biotechnology
- Vol. 36 (8) , 741-743
Building Capacity for a Global Genome Editing Observatory: Institutional Design
- 1 July 2018
- Published by Elsevier in Trends in Biotechnology
- Vol. 36 (7) , 639-641
Building Capacity for a Global Genome Editing Observatory: Conceptual Challenges
- 1 July 2018
- Published by Elsevier in Trends in Biotechnology
- Vol. 36 (7) , 639-641
Building Capacity for a Global Genome Editing Observatory: Conceptual Challenges
- Open Access
- 3 July 2017
- Published by SAGE Publications in Big Data & Society
- Vol. 4 (2)
A science that knows no country: Pandemic preparedness, global risk, sovereign science
This paper examines political norms and relationships associated with governance of pandemic risk. Through a pair of linked controversies over scientific access to H5N1 flu virus and genomic data, it examining the duties, obligations, and allocations of authority articulated around the imperative for globally free-flowing information and around the corollary imperative for a science that is set free to produce such information. It argues that scientific regimes are laying claim to a kind of sovereignty, particularly in moments where scientific experts call into question the legitimacy of claims grounded in national sovereignty, by positioning the norms of scientific practice, including a commitment to unfettered access to scientific information and to the authority of science to declare what needs to be known, as essential to global governance. Scientific authority occupies a constitutional position insofar as it figures centrally in the repertoire of imaginaries that shape how a global community is imagined: what binds that community together and what shared political commitments, norms, and subjection to delegated authority are seen as necessary for it to be rightly governed.
- 3 July 2017
- Published by SAGE Publications in Big Data & Society
- Vol. 4 (2)
Open AccessA science that knows no country: Pandemic preparedness, global risk, sovereign science
This paper examines political norms and relationships associated with governance of pandemic risk. Through a pair of linked controversies over scientific access to H5N1 flu virus and genomic data, it examining the duties, obligations, and allocations of authority articulated around the imperative for globally free-flowing information and around the corollary imperative for a science that is set free to produce such information. It argues that scientific regimes are laying claim to a kind of sovereignty, particularly in moments where scientific experts call into question the legitimacy of claims grounded in national sovereignty, by positioning the norms of scientific practice, including a commitment to unfettered access to scientific information and to the authority of science to declare what needs to be known, as essential to global governance. Scientific authority occupies a constitutional position insofar as it figures centrally in the repertoire of imaginaries that shape how a global community is imagined: what binds that community together and what shared political commitments, norms, and subjection to delegated authority are seen as necessary for it to be rightly governed.
- 1 December 2015
- Published by Springer Nature in Monash Bioethics Review
- Vol. 33 (4) , 301-324
Promising waste: biobanking, embryo research, and infrastructures of ethical efficiency
Biobanks are custodial institutions that enhance the utility and value of biological materials by collecting and curating them. Their custodial functions tend to include ethical oversight and governance. This paper explores how biobanks increase the value of biological materials by standardizing routines of governance in order to engender “ethical efficiency.” Focusing in particular upon banking of human embryos for research, the article offers an historical account of how human embryos came to be “waste” available for use by researchers in the US. It offers a case study of a human embryo biobank and the practices of ethical governance that the biobank employs to capture this waste and convert it into a valuable resource for research use. The article draws attention to the ways biobanks’ emphasis on efficiency and resolving problems of ethical governance up front codifies otherwise contested normative relationships and authorizes uses of human biological materials that some see as ethically problematic, even as it eliminates institutionalized mechanisms of reflection in which such problems would otherwise be acknowledged and confronted.
- 1 December 2015
- Published by Springer Nature in Monash Bioethics Review
- Vol. 33 (4) , 301-324
Promising waste: biobanking, embryo research, and infrastructures of ethical efficiency
Biobanks are custodial institutions that enhance the utility and value of biological materials by collecting and curating them. Their custodial functions tend to include ethical oversight and governance. This paper explores how biobanks increase the value of biological materials by standardizing routines of governance in order to engender “ethical efficiency.” Focusing in particular upon banking of human embryos for research, the article offers an historical account of how human embryos came to be “waste” available for use by researchers in the US. It offers a case study of a human embryo biobank and the practices of ethical governance that the biobank employs to capture this waste and convert it into a valuable resource for research use. The article draws attention to the ways biobanks’ emphasis on efficiency and resolving problems of ethical governance up front codifies otherwise contested normative relationships and authorizes uses of human biological materials that some see as ethically problematic, even as it eliminates institutionalized mechanisms of reflection in which such problems would otherwise be acknowledged and confronted.
- Open Access
- 31 January 2011
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 141 (0506) , w13144
Disease modelling using pluripotent stem cells: making sense of disease from bench to bedside
New advances in human stem cell biology now permit the derivation of disease-specific induced pluripotent (iPS) stem cell lines, so-called “disease-in-a-dish” (DIAD) models. This is a promising approach for the study of disease phenotypes at the cellular and molecular level, both because such human cell lines may produce more faithful experimental models of disease than can be produced using non-human organisms, and because reprogrammed cell lines can provide a virtually infinite supply of cells without requiring additional tissue donation. However, expectations placed on this emerging technology privilege the laboratory over the clinic as the site for making sense of disease, thereby distracting from the socially embedded meanings of disease and reorienting how the goals of medicine are imagined. Here we identify and review the implications of this area of research for clinical approaches to disease. We argue that there is a central place for the larger medical community and patients in the very construction of experimental research programs and the expectations placed thereon. By attending to the constellation of social factors that inform understanding, treatments and experiences of disease, DIAD projects can be more effectively placed in the service of clinical goals, in both their research design and in the forms of innovation they claim to anticipate. Stem cells are increasingly considered to be at a forefront of medicine. Billions of Euros have been raised by both private and public institutions to battle disease and improve healthcare. Fundamentally immature, stem cells represent a plastic substrate for modern molecular bioengineering to generate therapeutics for diseased and injured patients [1, 2]. Research involving these plastic cells lies at the nexus of molecular research and clinical application. In this article, we discuss and anticipate emerging issues for clinical medicine that will likely unfold as this research progresses.
- 31 January 2011
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 141 (0506) , w13144
Open AccessDisease modelling using pluripotent stem cells: making sense of disease from bench to bedside
New advances in human stem cell biology now permit the derivation of disease-specific induced pluripotent (iPS) stem cell lines, so-called “disease-in-a-dish” (DIAD) models. This is a promising approach for the study of disease phenotypes at the cellular and molecular level, both because such human cell lines may produce more faithful experimental models of disease than can be produced using non-human organisms, and because reprogrammed cell lines can provide a virtually infinite supply of cells without requiring additional tissue donation. However, expectations placed on this emerging technology privilege the laboratory over the clinic as the site for making sense of disease, thereby distracting from the socially embedded meanings of disease and reorienting how the goals of medicine are imagined. Here we identify and review the implications of this area of research for clinical approaches to disease. We argue that there is a central place for the larger medical community and patients in the very construction of experimental research programs and the expectations placed thereon. By attending to the constellation of social factors that inform understanding, treatments and experiences of disease, DIAD projects can be more effectively placed in the service of clinical goals, in both their research design and in the forms of innovation they claim to anticipate. Stem cells are increasingly considered to be at a forefront of medicine. Billions of Euros have been raised by both private and public institutions to battle disease and improve healthcare. Fundamentally immature, stem cells represent a plastic substrate for modern molecular bioengineering to generate therapeutics for diseased and injured patients [1, 2]. Research involving these plastic cells lies at the nexus of molecular research and clinical application. In this article, we discuss and anticipate emerging issues for clinical medicine that will likely unfold as this research progresses.